These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22920938)

  • 21. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
    Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
    Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Zhu W; Fu W; Hu L
    Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
    Wang WJ; Long LM; Yang N; Zhang QQ; Ji WJ; Zhao JH; Qin ZH; Wang Z; Chen G; Liang ZQ
    Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK
    PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
    Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells.
    Yu Y; Yu X; Ma J; Tong Y; Yao J
    Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
    Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
    Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
    Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.
    Wang Y; Yu Q; He X; Romigh T; Altemus J; Eng C
    Mol Cancer Ther; 2014 Feb; 13(2):517-27. PubMed ID: 24356815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Qian Z; Zhang L; Cai Z; Sun L; Wang H; Yi Q; Wang M
    Leuk Res; 2011 Mar; 35(3):380-6. PubMed ID: 21047686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
    Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D
    Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
    Haritunians T; Mori A; O'Kelly J; Luong QT; Giles FJ; Koeffler HP
    Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
    Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
    Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
    Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
    Vazquez N; Lopez A; Cuello V; Persans M; Schuenzel E; Innis-Whitehouse W; Keniry M
    Cancer Treat Res Commun; 2021; 27():100340. PubMed ID: 33636591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.